{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:30:09Z","timestamp":1781796609836,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202401189ZYT"],"award-info":[{"award-number":["YDZJ202401189ZYT"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jilin Health Science and Technology Capacity Enhancement Project","award":["2022Lc116"],"award-info":[{"award-number":["2022Lc116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03723-9","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:44:47Z","timestamp":1766551487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["External validation of the updated international IgA nephropathy prediction tool in a Chinese population"],"prefix":"10.1186","volume":"31","author":[{"given":"Xinru","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"5","key":"3723_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435\u201342.","journal-title":"Semin Nephrol"},{"key":"3723_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010189","author":"F Sallustio","year":"2019","unstructured":"Sallustio F, Curci C, Di Leo V, Gallone A, Pesce F, Gesualdo L. A new vision of IgA nephropathy: the missing link. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms21010189.","journal-title":"Int J Mol Sci"},{"key":"3723_CR3","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117\u2013s314.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"1","key":"3723_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","volume":"102","author":"SJ Barbour","year":"2022","unstructured":"Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Application of the International IgA nephropathy prediction tool one or two years post-biopsy. Kidney Int. 2022;102(1):160\u201372.","journal-title":"Kidney Int"},{"issue":"1","key":"3723_CR5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1159\/000548271","volume":"11","author":"L Xu","year":"2025","unstructured":"Xu L, Chen P, Liu L, Shi S, Zhou X, Lv J, et al. External validation of the post-biopsy International IgA nephropathy prediction tool models over extended follow-up in an Asian cohort. Kidney Dis (Basel). 2025;11(1):661\u201373.","journal-title":"Kidney Dis (Basel)"},{"issue":"9","key":"3723_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3723_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942\u201352.","journal-title":"JAMA Intern Med"},{"key":"3723_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.","journal-title":"BMJ"},{"issue":"3","key":"3723_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214256","volume":"14","author":"S Bagchi","year":"2019","unstructured":"Bagchi S, Lingaiah R, Mani K, Barwad A, Singh G, Balooni V, et al. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study. PLoS ONE. 2019;14(3):e0214256.","journal-title":"PLoS ONE"},{"issue":"9","key":"3723_CR10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2012010053","volume":"23","author":"F Berthoux","year":"2012","unstructured":"Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23(9):1579\u201387.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"3723_CR11","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.2215\/CJN.13711118","volume":"14","author":"P Chen","year":"2019","unstructured":"Chen P, Yu G, Zhang X, Xie X, Wang J, Shi S, et al. Plasma galactose-deficient IgA1 and C3 and CKD progression in IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(10):1458\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3723_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12882-023-03198-y","volume":"24","author":"S El\u00edasd\u00f3ttir","year":"2023","unstructured":"El\u00edasd\u00f3ttir S, Khramova A, Saeed A, Guron G, Boi R, M\u00f6lne J, et al. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression. BMC Nephrol. 2023;24(1):160.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3723_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/0886022X.2021.1879852","volume":"43","author":"P He","year":"2021","unstructured":"He P, Wang H, Huang C, He L. Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis. Ren Fail. 2021;43(1):488\u201399.","journal-title":"Ren Fail"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03723-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03723-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03723-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:44:52Z","timestamp":1769517892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03723-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3723"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03723-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Second Hospital of Jilin University(No. 2024058) and the Ethics Committee of the First Hospital of Jilin University (No. 2024645) in accordance with the standards of the Declaration of Helsinki, and is registered at\n                      \n                      (ChiCTR2400093550).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"147"}}